Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 1/20 | 0.48 |
| ▸ | IGF1R | P08069 | 16/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.45 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.45 |
| ▸ | INSR | P06213 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL397202 | 1.00 | TNK2 (0.48) | TNK2IGF1RCYP3A4MAPK3MAPK1 | |
| Methylpiperazine SCHEMBL1131232 | 0.94 | TNK2 (0.44) | TNK2IGF1RCYP3A4MAPK3MAPK1 | |
| SCHEMBL19264282 | 0.88 | TNK2 (0.50) | TNK2IGF1RCYP3A4MAPK3MAPK1 | |
| SCHEMBL2967554 | 0.86 | TNK2 (0.61) | TNK2IGF1RCYP3A4MAPK3MAPK1 | |
| SCHEMBL398156 | 0.86 | TNK2 (0.61) | TNK2IGF1RCYP3A4MAPK3MAPK1 | |
| SCHEMBL10189260 | 0.86 | TNK2 (0.61) | TNK2IGF1RCYP3A4MAPK3MAPK1 | |
| SCHEMBL402204 | 0.86 | TNK2 (0.37) | TNK2IGF1RCYP3A4MAPK3MAPK1 | |
| SCHEMBL6938221 | 0.86 | TNK2 (0.37) | TNK2IGF1RCYP3A4MAPK3MAPK1 | |
| SCHEMBL27658563 | 0.84 | TNK2 (0.36) | TNK2IGF1RCYP3A4MAPK3MAPK1 | |
| SCHEMBL13812631 | 0.81 | TNK2 (0.42) | TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1973917-B1 | PROTEIN KINASE INHIBITORS | ABBVIE INC (US) | 2015-06-10 | — | — | EP | disclosed |
| US-7772231-B2 | Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors | ABBOTT LABORATORIES (US) | 2010-08-10 | — | — | US | disclosed |
| US-20070203143-A1 | PROTEIN KINASE INHIBITORS | ABBVIE INC. | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203143-A1 | PROTEIN KINASE INHIBITORS | PACSIN2, MAP3K20, PHKG1 | TNK2 39/4885IGF1R 1941/4885CYP3A4 4582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.